Certainly, it will be necessary to first identify the differential epitopes that are only recognized by the pathogenic anti-HRGEC antibodies (like LN1–4) and then develop a more specific assay for the detection of pathogenic anti-HRGEC antibodies in LN patients that may be helpful in the disease diagnosis and follow-up. Here, PHYH is linked to lobular neoplasia.